Salivary Alpha-Amylase Enzyme, Psychological Disorders, and Life Quality in Patients with Recurrent Aphthous Stomatitis

Abstract

Objective. The aim of this study was to evaluate stress, anxiety, and salivary alpha-amylase (SAA) activity in patients with recurrent aphthous stomatitis (RAS). The impact of this disease on the life quality was also evaluated. Design. Twenty-two patients with RAS and controls, matched by sex and age, were selected. Stress and anxiety were assessed using Lipp's Inventory of Stress Symptoms and Beck Anxiety Inventory. Life quality was assessed through the World Health Organization Quality of Life-bref (WHOQOL-BREF) and the Oral Health Impact Profile-14 (OHIP-14). Saliva samples were collected in the morning and afternoon and the SAA activity was analyzed by enzymatic kinetic method. Results. No significant difference was observed between the groups regarding the SAA activity (p = 0.306). Patients with RAS had higher scores of anxiety (p = 0.016). The scores of WHOQOL-BREF were significantly lower in patients with RAS. The values obtained through OHIP-14 were significantly higher in these patients (p = 0.002). Conclusion. RAS negatively affects the life quality. Patients with the disease have higher levels of anxiety, suggesting its association with the etiopathogenesis of RAS.

Validation of the HADS and PSS‐10 and a cross‐sectional study of psychological status in patients with recurrent aphthous stomatitis

“…Results from the factor analysis demonstrated that a bi-factor model, with all items loading onto general factor with two group factors, provides the best fit to the HADS and PSS-10 data of patients with RAS than the originally proposed model. These findings were consistent with recent validation studies of both scales in various medical diagnoses, 19,20 Several studies have found that patients with RAS had higher level of anxiety, 21,22 depression, 23 distress, 24 and psychological stress 25 when compared to healthy individuals, while some studies did not find the difference between two groups. 4,26 The prevalence of anxiety symptoms in the present RAS cohort was higher than that reported in a previous study of Croatian patients (42.5% vs 24.47%), whereas the figures for depressive symptoms were much lower (18.3% vs 47.06%).…”

“…Several studies have found that patients with RAS had higher level of anxiety, depression, distress, and psychological stress when compared to healthy individuals, while some studies did not find the difference between two groups . The prevalence of anxiety symptoms in the present RAS cohort was higher than that reported in a previous study of Croatian patients (42.5% vs 24.47%), whereas the figures for depressive symptoms were much lower (18.3% vs 47.06%) .…”

Relation between salivary cortisol and alpha amylase levels and anxiety in Egyptian patients with minor recurrent aphthous stomatitis

“…This coincides with the results revealed by Nadendla et al [23] who used HAS for the assessment of the anxiety in RAS patients which is the same scale used in this study. Despite different scales were used by Albanidou-Farmaki et al [10] , Gallo et al [9] , Bilal et al [27] , and Cardoso et al [24] who used Spielberger's State-Trait Anxiety Inventory (STAI), Symptoms of Stress List (SSL), STAI; Beck Depression Inventory (BDI), and Lipp's Inventory of Stress Symptoms; DDI respectively similar findings were found by them regarding the evaluation of anxiety in RAS patients. But this was not in accordance with findings previously showed by Picek et al [8] , who revealed no significant differences between the controls and RAS patients in the acute state in relation to anxiety therapy or state sores.…”

“…The RAS is a common painful disorder affecting oral mucous membrane in the form of single or multiple ulcerative lesions characterized by recurrence [22] . These lesions induce pain and may interfere with eating, speaking, and oral cleanliness, prompting more serious effect on patient's life quality [24] .…”

“…According to Cardoso et al [24] , median SAA (U/ ml) was 42.72 (25.18-75.55) in controls, 45.50 (35.68-97.47) in RAS patients. The mean was calculated as 46.54 in controls and 56.04 in RAS patients using the formula below: We found that a simple formula (5):…”